OpenAlex
PricingAboutJobs
Log inGet started
Work

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

HTML PDF

Year: 2021
Type: article
Source: The Lancet Oncology
DOI: 10.1016/s1470-2045(21)00155-8
Authors: Barliz Waissengrin, Abed Agbarya, Esraa Safadi, Hagit Padova, Ido Wolf
Institutions: Tel Aviv Sourasky Medical Center, Bnai Zion Medical Center, Tel Aviv University
Language: English

Topic: SARS-CoV-2 and COVID-19 Research
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: BNT162b2 mRNA vaccine, COVID-19 vaccination, cancer patients, immune checkpoint inhibitors, vaccine safety, systemic cancer therapy, COVID-19 mortality risk
SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Teva Pharmaceutical Industries
OpenAlex ID: W3145657260
FWCI: 14.37
Cites: 7
Cited by: 195
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms